1 PRODUCT NAME
Rubifen
Rubifen SR
Methylphenidate hydrochloride (USP) 5 mg, 10 mg and 20 mg
Methylphenidate hydrochloride (USP) 20 mg sustained release tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 5mg tablet contains methylphenidate 5mg
Each 10mg tablet contains methylphenidate 10mg
Each 20mg tablet contains methylphenidate 20mg

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM
Rubifen immediate release 5, 10 and 20 mg tablets: round white tablet with slightly bevelled edges, marked RU-5, RU-10 or RU-20 containing 5 mg, 10 mg and 20 mg methylphenidate respectively with a score mark on the 10 mg tablets.

Rubifen sustained release 20 mg tablets: oblong white or white-cream smooth tablet containing 20 mg methylphenidate in a modified release formulation.

4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD was previously known as attention-deficit disorder or minimal brain dysfunction. Other terms used to describe this behavioural syndrome include: hyperkinetic disorder, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction and psycho-organic syndrome of children.

Rubifen is indicated as part of a comprehensive treatment program which typically includes psychological, educational and social measures and is aimed at stabilising children with a behavioural syndrome characterised by moderate to severe distractibility, short attention span, hyperactivity, emotional lability and impulsivity. The diagnosis should be made according to DSM-IV criteria or the guidelines in ICD-10. Non-localising (soft) neurological signs, learning disability and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

Special Diagnostic Considerations for ADHD
The specific etiology of this syndrome is unknown, and there is no single diagnostic test. Proper diagnosis requires medical and neuropsychological, educational and social investigation. Characteristics commonly reported include: history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and abnormal EEG. Learning may or may not be impaired. The diagnosis
must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics. Drug treatment is not indicated in all children with this syndrome. Stimulants are not indicated in children with symptoms secondary to environmental factors (child abuse in particular) and/or primary psychiatric disorder, including psychosis. Appropriate educational placement is essential, and psychosocial intervention is generally necessary. Where remedial measures alone prove insufficient, the decision to prescribe a stimulant must be based on rigorous assessment of the severity of the child’s symptoms.

Narcolepsy
Symptoms include daytime sleepiness, inappropriate sleep episodes, and sudden loss of voluntary muscle tone.

4.2 Dose and method of administration

Dose titration

Careful dose titration is necessary at the start of treatment with methylphenidate. Dose titration should be started at the lowest possible dose.

Other strengths of this medicinal product and other methylphenidate-containing products may be available.

The maximum daily dosage of methylphenidate is 60 mg.

Immediate release tablets

The dosage of Rubifen should be individualised according to the patient’s clinical needs and responses. Do not halve tablets. Dose equivalence when the tablet is divided has not been established.

In the treatment of ADHD, an attempt should be made to time administration to coincide with the periods of greatest academic, behavioural and social stress.

Rubifen should be started at a low dose, with increments at weekly intervals. Daily doses above 60 mg are not recommended.

If symptoms do not improve after dose titration over a period of one month, the drug should be discontinued.

If symptoms worsen or other adverse effects occur, the dosage should be reduced or, if necessary, the drug discontinued.

If the effect of the drug wears off too early in the evening, disturbed behaviour and/or inability to go to sleep may recur. A small evening dose of the normal tablet or an afternoon dose of the SR tablet may help to solve this problem.

Rubifen should be discontinued periodically to assess the child’s condition. Improvement may continue when the drug is temporarily or permanently discontinued.
Drug treatment should not, and need not, be indefinite. It can usually be discontinued during or after puberty. However, ADHD may continue into adulthood and treatment with Rubifen may be beneficial to those patients after puberty.

Pre-treatment screening

Prior to prescribing, it is necessary to conduct a baseline evaluation of a patient’s cardiovascular status including blood pressure and heart rate. A comprehensive history should document concomitant medications, past and present co-morbid medical and psychiatric disorders or symptoms, family history of sudden cardiac/unexplained death and accurate recording of pre-treatment height and weight on a growth chart (see sections 4.3 and 4.4)

Ongoing monitoring

Growth, psychiatric and cardiovascular status should be continuously monitored (see also Section 4.4).

- Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every 6 months;
- height, weight and appetite should be recorded at least 6 monthly with maintenance of a growth chart;
- development of de novo or worsening of pre-existing psychiatric disorders should be monitored at every adjustment of dose and then at least every 6 months and at every visit.

Patients should be monitored for the risk of diversion, misuse and abuse of methylphenidate.

Long-term (more than 12 months) use in children and adolescents

The safety and efficacy of long term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. Methylphenidate treatment is usually discontinued during or after puberty. The physician who elects to use methylphenidate for extended periods (over 12 months) in children and adolescents with ADHD should periodically re-evaluate the long term usefulness of the drug for the individual patient with trial periods off medication to assess the patient’s functioning without pharmacotherapy. It is recommended that methylphenidate is de-challenged at least once yearly to assess the child’s condition (preferable during times of school holidays). Improvement may be sustained when the drug is either temporarily or permanently discontinued.

Dose reduction and discontinuation

Treatment must be stopped if the symptoms do not improve after appropriate dosage adjustment over a one-month period. If paradoxical aggravation of symptoms or other serious adverse events occur, the dosage should be reduced or discontinued.

In the treatment of narcolepsy, the usual oral dose is 20 to 30 mg daily in divided doses, normally 30 to 45 minutes before meals, but the effective dose may range from 10 to 60 mg daily.
In hyperactivity disorders in children aged 6 years and over, the usual initial dose is 5 mg once or twice daily by mouth, increased if necessary by 5 to 10 mg at weekly intervals to a maximum of 60 mg daily in divided doses. Methylphenidate maybe given before breakfast and lunch. A later dose may be considered if the effect wears off in the evening causing rebound hyperactivity.

**Sustained release tablets**

Rubifen SR Tablets have a duration of action of about 8 hours. They may therefore be used when a prolonged effect is desired exceeding the duration of action of conventional Rubifen tablets. Rubifen SR tablets must be swallowed whole and never crushed or chewed. Rubifen SR tablets should not be split or divided. They should be taken after meals, preferably after a substantial breakfast (see Pharmacokinetic properties) for maximum duration of effect.

It may be necessary to use a combination of the standard immediate release and SR tablets in some patients to achieve the optimal clinical response. As the duration of action of Rubifen SR tablets is variable from patient to patient, it may not be possible to avoid administration of a Rubifen dose during the middle part of the day in all patients. The total absorption and duration of action of Rubifen SR tablets are maximised when it is taken with a meal.

The total daily dose should be similar to that required if the immediate formulation is used. In the fasted state, Rubifen SR 20 mg gives similar blood concentration to that expected following two Rubifen 10 mg immediate release tablets (with the second being taken four hours after the first).

### 4.3 Contraindications

- Hypersensitivity to methylphenidate or to any of the excipients in Rubifen (see List of Excipients)
- Anxiety, tension, agitation
- Hyperthyroidism
- Glaucoma
- Phaeochromocytoma
- Diagnosis of motor tics or tics in siblings with tics
- Diagnosis or family history of Tourette's syndrome
- During treatment with non-selective, irreversible monoamine oxidase (MAO) inhibitors, or within a minimum of 14 days of discontinuing those drugs, due to risk of hypertensive crisis (see section 4.5)
- Diagnosis or history of severe depression, anorexia nervosa/anorexic disorders, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic/borderline personality disorder.
- Diagnosis or history of severe and episodic (Type I) Bipolar (affective) Disorder (that is not well-controlled)
- pre-existing cardiovascular disorders including severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies (disorders caused by the dysfunction of ion channels).
- pre-existing cerebrovascular disorders cerebral aneurysm, vascular abnormalities including vasculitis or stroke.
4.4 Special warnings and precautions for use

Treatment with Rubifen is not indicated in all cases of Attention-Deficit/Hyperactivity disorder, and should be considered only after detailed history-taking and evaluation. The decision to prescribe Rubifen should depend on an assessment of the severity of symptoms and their appropriateness to the child’s age, and not simply on the presence of one or more abnormal behavioural characteristics. Where these symptoms are associated with acute stress reactions, treatment with Rubifen is usually not indicated.

Long-term use (more than 12 months) in children and adolescents

The safety and efficacy of long term use of methylphenidate has not been systematically evaluated in controlled trials. Methylphenidate treatment should not and need not, be indefinite. Methylphenidate treatment is usually discontinued during or after puberty. Patients on long-term therapy (i.e. over 12 months) must have careful ongoing monitoring according to the guidance in sections 4.2 and 4.4, for cardiovascular status, growth, appetite, development of de novo or worsening of pre-existing psychiatric disorders. Psychiatric disorders to monitor for are described below, and include (but are not limited to) motor or vocal tics, aggressive or hostile behaviour, agitation, anxiety, depression, psychosis, mania, delusions, irritability, lack of spontaneity, withdrawal and excessive perseveration.

The physician who elects to use methylphenidate for extended periods (over 12 months) in children and adolescents with ADHD should periodically re-evaluate the long term usefulness of the drug for the individual patient with trial periods off medication to assess the patient’s functioning without pharmacotherapy. It is recommended that methylphenidate is de-challenged at least once yearly to assess the child’s condition (preferably during times of school holidays). Improvement may be sustained when the drug is either temporarily or permanently discontinued.

Use in the elderly

Methylphenidate should not be used in the elderly. Safety and efficacy has not been established in this age group.

Use in children under 6 years of age

Methylphenidate should not be used in children under the age of 6 years. Safety and efficacy in this age group has not been established.

Cardiovascular status

Patients who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden cardiac or unexplained death or malignant arrhythmia,) and physical exam to assess for the presence of cardiac disease, and should receive further specialist cardiac evaluation if initial findings suggest such history or disease. Patients who develop symptoms such as palpitations, exertional chest
pain, unexplained syncope, dyspnoea or other symptoms suggestive of cardiac disease during methylphenidate treatment should undergo a prompt specialist cardiac evaluation.

Analyses of data from clinical trials of methylphenidate in children and adolescents with ADHD showed that patients using methylphenidate may commonly experience changes in diastolic and systolic blood pressure of over 10 mmHg relative to controls. The short- and long-term clinical consequences of these cardiovascular effects in children and adolescents are not known, but the possibility of clinical complications cannot be excluded as a result of the effects observed in the clinical trial data. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate.

Cardiovascular status should be carefully monitored. Blood pressure and pulse should be recorded on a centile chart at each adjustment of dose and then at least every 6 months.

The use of methylphenidate is contraindicated in certain pre-existing cardiovascular disorders unless specialist paediatric cardiac advice has been obtained.

Sudden death and pre-existing cardiac structural abnormalities or other serious cardiac disorders.

Sudden death has been reported in association with the use of stimulants of the central nervous system at usual doses in children, some of whom had cardiac structural abnormalities or other serious heart problems. Although some serious heart problems alone may carry an increased risk of sudden death, stimulant products are not recommended in children or adolescents with known cardiac structural abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant medicine.

**Priapism**

Prolonged and painful erections requiring immediate medical attention (sometimes including surgical intervention) have been reported with methylphenidate products in both paediatric and adult patients. Priapism can develop after prolonged periods of use, but most often subsequent to an increase in dose. Priapism has also developed during a period of methylphenidate withdrawal (e.g. drug holidays or during discontinuation). Patients who develop abnormally sustained erections or frequent and painful erections should seek immediate medical attention.

**Misuse and Cardiovascular Events**

Misuse of stimulants of the central nervous system may be associated with sudden death and other serious cardiovascular adverse events.

**Cerebrovascular Conditions**
Patients with pre-existing CNS abnormalities, e.g., cerebral aneurysm and/or other vascular abnormalities such as vasculitis or pre-existing stroke should not be treated with Rubifen. Patients with additional risk factors (history of cardiovascular disease, concomitant medications that elevate blood pressure) should be assessed regularly for neurological/psychiatric signs and symptoms after initiating treatment with Rubifen (see above paragraph on Cardiovascular Conditions and below for Interactions).

Cerebral vasculitis appears to be a very rare idiosyncratic reaction to methylphenidate exposure. There is little evidence to suggest that patients at higher risk can be identified and the initial onset of symptoms may be the first indication of an underlying clinical problem. Early diagnosis, based on a high index of suspicion, may allow the prompt withdrawal of methylphenidate and early treatment. The diagnosis should therefore be considered in any patient who develops new neurological symptoms that are consistent with cerebral ischemia during methylphenidate therapy. These symptoms could include severe headache, numbness, weakness, paralysis, and impairment of coordination, vision, speech, language or memory.

Treatment with methylphenidate is not contraindicated in patients with hemiplegic cerebral palsy

Psychiatric

Co-morbidity of psychiatric disorders in ADHD is common and should be taken into account when prescribing stimulant products. Treatment of ADHD with stimulant products including Rubifen should not be initiated in patients with acute psychosis, acute mania or acute suicidality. These acute conditions should be treated and controlled before ADHD treatment is considered.

**Development or worsening of psychiatric disorders should be monitored at every adjustment of dose, then at least every 6 months, and at every visit; discontinuation of treatment may be appropriate.**

Psychotic symptoms

Psychotic symptoms, including visual and tactile hallucinations have been reported in patients administered usual prescribed doses of stimulant products, including Rubifen (see section 4.8). Physicians should consider treatment discontinuation.

Clinical experience suggests that Rubifen may exacerbate symptoms of behavioural disturbance and thought disorder in psychotic children.

**Aggressive behaviour**

Emergent aggressive behaviour or an exacerbation of baseline aggressive behaviour has been reported during stimulant therapy, including Rubifen. However, patients with ADHD may experience aggression as part of their medical condition. Therefore causal association with treatment is difficult to assess. Physicians should evaluate the need for adjustment of treatment regimen in patients experiencing these behavioural changes, bearing in mind that upwards or downwards titration may be appropriate. Treatment interruption can be considered.
Suicidal tendency

Patients with emergent suicidal ideation and behaviour during treatment for ADHD should be evaluated immediately by their physician. The physician should initiate appropriate treatment of the underlying psychiatric condition and consider a possible change in the ADHD treatment regimen.

Growth

Moderately reduced weight gain and growth retardation have been reported with the long-term use of methylphenidate in children.

The effects of methylphenidate on final height and final weight are currently unknown and being studied.

Growth should be monitored during methylphenidate treatment: height, weight and appetite should be recorded at least 6 monthly with maintenance of a growth chart. Patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.

Seizures

Methylphenidate should be used with caution in patients with epilepsy. Methylphenidate may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and rarely in patients without a history of convulsions and no EEG abnormalities. If seizure frequency increases or new-onset seizures occur, methylphenidate should be discontinued.

Abuse, misuse and diversion

Patients should be carefully monitored for the risk of diversion, misuse and abuse of methylphenidate.

Methylphenidate should be used with caution in patients with known drug or alcohol dependency because of a potential for abuse, misuse or diversion.

Chronic abuse of methylphenidate can lead to marked tolerance and psychological dependence with varying degrees of abnormal behaviour. Frank psychotic episodes can occur, especially in response to parenteral abuse.

Patient age, the presence of risk factors for substance use disorder (such as co-morbid oppositional-defiant or conduct disorder and bipolar disorder), previous or current substance abuse should all be taken into account when deciding on a course of treatment for ADHD. Caution is called for in emotionally unstable patients, such as those with a history of drug or alcohol dependence, because such patients may increase the dosage on their own initiative.
For some high-risk substance abuse patients, methylphenidate or other stimulants may not be suitable and non-stimulant treatment should be considered.

**Withdrawal**

Careful supervision is required during drug withdrawal, since this may unmask depression as well as chronic over-activity. Some patients may require long-term follow up.

Careful supervision is required during withdrawal from abusive use since severe depression may occur.

**Pregnancy-embryonal/foetal development**

Methylphenidate is considered to be possibly teratogenic in rabbits. Spina bifida with malrotated hind limbs was observed in two separate litters at a dose of 200 mg/kg/day. This dose was approximately 116-fold higher than the maximum recommended human dose (MRHD) of 60 mg. A second study was conducted with a high dose of 300 mg/kg, which was considered maternally toxic. No spina bifida was seen, however, in 12 litters (92 foetuses) surviving.

Methylphenidate is not teratogenic in rats. Development foetal toxicity was noted at a high dose of 75 mg/kg (44-fold higher than the MRHD) and consisted of an increase of the instance of foetuses with delayed ossification of the skull and hyoid bones as well as foetuses with short supernumerary ribs (see Use During Pregnancy and lactation).

**Carcinogenesis-mutagenesis**

In a lifetime carcinogenicity study carried out in B6C3F1 mice, methylphenidate caused an increase in hepatocellular adenomas (a benign tumour) and, in males only, an increase in hepatoblastomas (a malignant tumour) at daily doses of approximately 60 mg/kg/day (about 35-fold-higher than the MRHD). There was no overall increase in the number of malignant hepatic tumours. The mouse strain used is particularly sensitive to the development of hepatic tumours, and the significance of these results to humans is unknown.

Similar studies in F344 rats showed no evidence of carcinogenicity.

Sister chromatid exchange and chromosome aberrations were elevated in an in vitro test on cultured ovary cells of Chinese hamster but no mutagenic effects were observed in two further in vitro tests (Ames reverse mutation test, mouse lymphoma forward mutation test). In an in vivo study of the effect of methylphenidate on mouse bone marrow cells (micronucleus test), in which doses up to 250 mg/kg were given, there was no evidence of clastogenic or aneugenic effects. The strain used for this in vivo assay was the B6C3F1 mouse, the same strain that produced a positive response in the mouse carcinogenicity study.

The US Food and Drugs Administration examined data from the Surveillance, Epidemiology and End Results (SEER) database for the years 1973 to 1991 and found that the estimated incidence of hepatoblastoma in the general population was not greater than 1 in 10 million person years.
A total of 174 cases of hepatoblastoma were reported by the SEER for the period 1973 to 1995. Age-adjusted incidence rate was very low (IR=0.0382 per 100,000 person-years). The majority of the cases (149 out of 174) were diagnosed among the age group 0 to 4 years old, which is in accordance with the natural history of the disease. For the age group 5 to 24 years old the rates of hepatoblastoma were very low with few or no cases reported.

On the basis of experience since marketing Methylphenidate hydrochloride, there is no evidence that the incidence is higher in patients receiving Methylphenidate hydrochloride.

**Juvenile neurobehavioral development**

Repeated oral administration of methylphenidate to young rats identified decreased spontaneous locomotor activity at 50 mg/kg/day (29-fold higher than the MRHD), due to an exaggerated pharmacological activity of methylphenidate. A deficit in the acquisition of a specific learning task was also observed, only in females and at the highest dose of 100 mg/kg/day (58-fold higher than the MRHD). The clinical relevance of these findings is unknown.

Unlike these preclinical findings, long-term administration of methylphenidate in children with ADHD is well tolerated and improves the school performance. Thus the clinical experience does not suggest that these learning and behavioral results in rats are clinically relevant.

**Others**

This product contains methylphenidate which may induce a false positive laboratory test for amphetamines, particularly with immunoassay screen test.

The long-term safety of treatment with methylphenidate is not fully known. In the event of Leukopenia, thrombocytopenia, anaemia or other alterations, including those indicative of serious renal or hepatic disorders, discontinuation of treatment should be considered.

### 4.5 Interaction with other medicines and other forms of interaction

Salbutamol and non-selective β-blocking agents, such as propranolol, should not usually be prescribed together.

Salbutamol is not contra-indicated in patients under treatment with monoamine oxidase inhibitors (MAOIs).

### 4.6 Fertility, pregnancy and lactation

**Category B2**

There is a limited amount of data from the use of methylphenidate in pregnant women.

Cases of neonatal cardiorespiratory toxicity, specifically fetal tachycardia and respiratory distress have been reported in spontaneous case reports.
Studies in animals have only shown evidence of reproductive toxicity at maternally toxic doses.

Methylphenidate is not recommended for use during pregnancy unless a clinical decision is made that postponing treatment may pose a greater risk to the pregnancy.

Methylphenidate has been found in the breast-milk of a woman treated with methylphenidate.

There is one case report of an infant who experienced an unspecified decrease in weight during the period of exposure but recovered and gained weight after the mother discontinued treatment with methylphenidate. A risk to the suckling child cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from methylphenidate therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

4.7 Effects on ability to drive and use machines
Rubifen may cause dizziness, drowsiness and visual disturbances including difficulties with accommodation, diplopia and blurred vision. It is therefore advisable to exercise caution when driving, operating machinery, or engaging in other potentially hazardous activities.

4.8 Undesirable effects
Nervousness and insomnia are very common adverse reactions that occur at the beginning of Rubifen treatment but can usually be controlled by reducing the dosage and/or omitting the afternoon or evening dose.

Decreased appetite is also common but usually transient. Abdominal pain, nausea and vomiting are common, usually occur at the beginning of treatment and may be alleviated by concomitant food intake.

Frequency estimate: very common ≥10 %, common ≥1 % to < 10 %; uncommon ≥0.1 % to < 1 %; rare ≥0.01 % to < 0.1 %; very rare < 0.01 %.

Blood and the lymphatic system disorders
Very rare: leucopenia, thrombocytopenia, anaemia
Unknown: pancytopenia

Immune system disorders
Very rare: hypersensitivity Reactions such as angioneurotic oedema, anaphylactic reactions, auricular swelling, bullous conditions, exfoliative conditions, urticarias, pruritis, rashes and eruptions

Metabolism and nutrition disorders
Common: anorexia, decreased appetite, moderately reduced weight and height gain during prolonged use in children*
Psychiatric disorders

Very common: insomnia, nervousness

Common: anorexia, affect lability, aggression, agitation, anxiety, depression, irritability, abnormal behaviour

Uncommon: psychotic disorders, auditory, visual, and tactile hallucinations, anger, suicidal ideation, mood altered, mood swings, restlessness, tearfulness, tics, worsening of pre-existing tics or Tourette's syndrome, hypervigilance, sleep disorder

Rare: mania, disorientation, libido disorder

Very rare: suicidal attempt (including completed suicide), transient depressed mood, abnormal thinking, apathy, repetitive behaviours, over-focussing,

Not known: delusions thought disturbances, confusional state, dependence.

Nervous system disorders

Common: headache, drowsiness, dizziness, dyskinesia, psychomotor hyperactivity

Uncommon: sedation, tremor

Very rare: convulsions, choreoathetoid movements, tics or exacerbation of existing tics and Tourette's syndrome, cerebral arteritis and/or occlusion migraines

Eye disorders

Uncommon: diplopia, blurred vision,

Rare: difficulties in visual accommodation, visual disturbance, mydiasis

Cardiac disorders

Common: tachycardia, palpitation, arrhythmias, changes in blood pressure and heart rate (usually an increase)

Rare: angina pectoris

Very rare: cardiac arrest, myocardial infarction

Not known: supraventricular tachycardia, bradycardia, ventricular extrasystoles, extrasystoles

Vascular disorders*

Common: hypertension

Uncommon:

Very rare: cerebral arteritis and/or occlusion, peripheral coldness, Raynaud's phenomenon

Respiratory, thoracic and mediastinal disorders

Common: cough, pharyngolaryngeal pain
Uncommon: dyspnoea

**Gastrointestinal disorders**
Common: abdominal pain, nausea, vomiting, dry mouth

**Hepatobiliary disorders**
Very rare: Abnormal liver function, ranging from transaminase elevation to hepatic coma

**Skin and subcutaneous tissue disorders**
Common: rash, pruritus, urticaria, fever, scalp hair loss
Very rare: thrombocytopenic purpura, exfoliative dermatitis, erythema multiforme

**Musculoskeletal and connective tissue disorders**
Common: arthralgia
Uncommon: myalgia, muscle twitching
Very rare: muscle cramps

**General disorders and administration site conditions**

Very rare reports of poorly documented neuroleptic malignant syndrome (NMS) have been received. In most of these reports, patients were also receiving other medications. It is uncertain what role Rubifen played in these cases.

**Investigations**
Common: changes in blood pressure and heart rate (usually an increase)*, weight decreased*
Uncommon: cardiac murmur*, hepatic enzyme increased.

Very rare: blood alkaline phosphatase increased, blood bilirubin increased, platelet count decreased, white blood count abnormal.

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/)

**4.9 Overdose**

**Symptoms**

Signs and symptoms of acute overdosage, mainly due to overstimulation of the central and sympathetic nervous systems, may include: vomiting, agitation, tremor, hyperreflexia, muscle twitching, convulsions (possibly followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitation, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes.
Treatment

Management consists in providing supportive measures, preventing self-injury and protecting the patient from external stimuli that would exacerbate the overstimulation already present. If the signs and symptoms are not too severe and the patient is conscious, the stomach can be evacuated by induction of vomiting or gastric lavage. If intoxication is severe, a carefully titrated dose of a short-acting barbiturate should be given before performing gastric lavage. Intensive care must be provided to maintain adequate circulation and respiratory exchange; external-cooling procedures may be required to reduce hyperpyrexia. The efficacy of peritoneal dialysis or extracorporeal haemodialysis for Rubifen overdosage has not been established.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Psychostimulants.

Rubifen is a mild CNS stimulant with more prominent effects on mental than on motor activities. Its mode of action in humans is not completely understood, but its stimulant effects are thought to be due to cortical stimulation and possibly to stimulation of the reticular activating system. The mechanism by which Rubifen exerts its mental and behavioural effects in children is not clearly established, nor is there conclusive evidence showing how these effects relate to the condition of the central nervous system.

5.2 Pharmacokinetic properties

Absorption

Immediate release tablets: After oral administration the active substance (methylphenidate hydrochloride) is rapidly and almost completely absorbed. Owing to extensive first-pass metabolism its systemic availability is only 30% (11-51%) of the dose. Ingestion with food accelerates absorption, but has no effect on the amount absorbed. Peak plasma concentrations of about 40 nmol/L (11 ng/mL) are reached on average 1-2 hours after administration of 0.30 mg/kg. Peak plasma concentrations vary markedly between patients. The area under the concentration-time curve (AUC) and the peak plasma concentration (Cmax) are proportional to the dose.

SR Tablets: In the fasted state, absorption of methylphenidate from Rubifen 20 mg SR tablets is 37% slower than with the conventional tablets and results in a smaller fluctuation of plasma concentration. Cmax is lower (by 40%) and is attained later (at 3 hours) but the total amount absorbed (AUC) is the same.

After a high-fat meal, both AUC (by 25%) and Cmax (by 27%) are significantly higher, although the rate of absorption (Cmax/AUC ratio) remains the same. Time to Cmax (Tmax) is also slightly faster after a high-fat meal (median Tmax = 2.5 hrs) as compared to without food (median Tmax = 3 hrs). As with immediate release tablets, there is considerable variation in plasma methylphenidate concentrations between patients.

Distribution
In blood, methylphenidate and its metabolites are distributed between plasma (57 %) and erythrocytes (43 %). Binding to plasma proteins is low (10-33 %). The apparent distribution volume is about 13.1 L/kg.

**Biotransformation**

Biotransformation of methylphenidate is rapid and extensive. Peak plasma concentrations of the main, de-esterified metabolite α-phenyl-2-piperidine acetic acid are attained about 2 hours after administration and are 30-50 times higher than those of the unchanged substance. The half-life of α-phenyl-2-piperidine acetic acid is about twice that of methylphenidate, and its mean systemic clearance is 0.17 L/h/kg. Only small amounts of hydroxylated metabolites (e.g. hydroxymethylphenidate and hydroxytritalinic acid) are detectable. Therapeutic activity seems to be principally due to the parent compound.

**Elimination**

Methylphenidate is eliminated from the plasma with a mean half-life of 2 hours. The apparent mean systemic clearance is 10 L/h/kg. After oral administration, 78-97 % of the dose is excreted in the urine and 1-3 % in the faeces in the form of metabolites within 48-96 hours. Only small quantities (<1 %) of unchanged methylphenidate appear in the urine. Most of the dose is excreted in the urine as α-phenyl-2-piperidine acetic acid (60-86 %). The elimination half-life and the cumulative urinary excretion of α-phenyl-2-piperidine acetic acid are not significantly different for SR tablets. Hence, in the fasted state, the total amount absorbed from one SR tablet and 20 mg in conventional tablet form is equal.

**Characteristics in patients**

There are no apparent differences in the pharmacokinetics of methylphenidate between hyperactive children and healthy adult volunteers. Elimination data from patients with normal renal function suggest that renal excretion of unchanged methylphenidate would hardly be diminished in the presence of impaired renal function. However, renal excretion of the metabolite α-phenyl-2-piperidine acetic acid may be reduced.

**5.3 Preclinical safety data**

Not applicable.

**6 PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

Rubifen (5 mg, 10 mg and 20 mg) contains calcium hydrogen phosphate dehydrate magnesium stearate, maize starch, and microcrystalline cellulose.

Rubifen SR (20 mg) contains cetyl alcohol, ethylcellulose, lactose, magnesium stearate, and opadry white Y-1-7000.

**6.2 Incompatibilities**

None known.

**6.3 Shelf life**

Rubifen (5 mg, 10 mg and 20 mg): 24 months

Rubifen SR (20 mg): 36 month
6.4 Special precautions for storage
Store at or below 25°C and protect from moisture

6.5 Nature and contents of container
Rubifen (5 mg, 10 mg and 20 mg): Blister pack, PVC/Al, 30 tablets

Rubifen SR (20 mg): Blister pack, PVC/PVdC AL (10 tbs/blister), 30 tablets

6.6 Special precautions for disposal
Not applicable.

7 MEDICINE SCHEDULE
Class B2 Controlled Drug

8 SPONSOR
AFT Pharmaceuticals Ltd.
Box 33-203
Takapuna
Auckland
Ph: (09) 4880232
Ph: (09) 4880234

9 DATE OF FIRST APPROVAL
16/03/2000

10 DATE OF REVISION OF THE TEXT
July 2019

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Date</th>
<th>Section(s) Changed</th>
<th>Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 2018</td>
<td>All</td>
<td>Reformat consistent with new Medsafe Data Sheet Template.</td>
</tr>
<tr>
<td>July 2019</td>
<td>6.1, 6.3, 6.4, 6.5</td>
<td>Added pharmaceutical particulars for Rubifen SR</td>
</tr>
</tbody>
</table>